

References

1. Stanley K. Design of randomized controlled trials. *Circulation*. 2007;115:1164-1169.
2. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. *JACC Cardiovasc Interv*. 2008;1:211-217.
3. Kovesdy CP, Kalantar-Zadeh K. Observational studies vs. randomized controlled trials: avenues to causal inference in nephrology. *Adv Chronic Kidney Dis*. 2012;19:11-18.
4. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. *Value Health*. 2007;10:326-335.
5. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. *J Am Heart Assoc*. 2016. doi:10.1161/JAHA.116.003725. Reproduced with permission of John Wiley & Sons, Inc.
6. Eliquis® (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc, New York, NY.
7. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365:981-992.
8. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365(11):981-992. [protocol] http://www.nejm.org/doi/suppl/10.1056/NEJMoa1107039/suppl_file/nejmo1107039_protocol.pdf. Accessed May 31, 2018.
9. Data on File: APIX060. Bristol-Myers Squibb Company, Princeton, NJ.
10. Data on File: APIX063. Bristol-Myers Squibb Company, Princeton, NJ.
11. Riley GF. Administrative and claims records as sources of health care cost data. *Med Care*. 2009;47:S51-S55.
12. Silverman LS. From randomized controlled trials to observational studies. *Am J Med*. 2009;122:114-120.
13. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011; 364:806-817.
14. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011; 364:806-817. [protocol] www.nejm.org/doi/suppl/10.1056/NEJMoa1007432/suppl_file/nejmoa1007432_protocol.pdf. Accessed August 9, 2016.